[EN] NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME<br/>[FR] NOUVEAUX COMPOSÉS POUR INHIBITEURS SÉLECTIFS D'HISTONE DÉSACÉTYLASES ET COMPOSITION PHARMACEUTIQUE LES COMPRENANT
申请人:CHONG KUN DANG PHARM CORP
公开号:WO2014178606A1
公开(公告)日:2014-11-06
The present invention relates to novel urea derivatives and, more particularly, to novel urea derivatives with histone deacetylase (HDAC) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, their use for the preparation of a medicaments comprising the same, a pharmaceutical composition comprising the same, a treatment method using the composition, and a method for preparing novel urea derivatives. The novel urea derivatives as selective histone deacetylase (HDAC) inhibitors are effective for the treatment of histone deacetylase-mediated diseases such as malignant tumors, inflammatory diseases, rheumatoid arthritis, neurodegeneration, etc.
本发明涉及新型尿素衍生物,更特别地涉及具有组蛋白去乙酰化酶(HDAC)抑制活性的新型尿素衍生物,其异构体,其药学上可接受的盐,它们用于制备包含相同成分的药物的用途,包含相同成分的药物组合物,使用该组合物的治疗方法,以及制备新型尿素衍生物的方法。作为选择性组蛋白去乙酰化酶(HDAC)抑制剂的新型尿素衍生物对于治疗组蛋白去乙酰化酶介导的疾病,如恶性肿瘤、炎症性疾病、类风湿性关节炎、神经退行性疾病等非常有效。